Anvylic

Anvyl Pharmaceuticals is a biotechnology company focused on the discovery and development of novel small molecule therapeutics for central nervous system (CNS) disorders. The company's lead research program centers on AVL-3288 (also known as Anvylic-3288), a first-in-class, selective positive allosteric modulator (PAM) of the alpha7 nicotinic acetylcholine receptor (alpha7 nAChR). This mechanism is designed to address cognitive impairment associated with conditions such as schizophrenia, Alzheimer's disease, and ADHD by enhancing endogenous neurotransmission without inducing receptor desensitization. AVL-3288 has completed Phase 1 clinical trials, demonstrating a favorable safety and pharmacokinetic profile in healthy volunteers. Anvyl Pharmaceuticals aims to provide innovative treatments that improve cognitive and memory functions through precise receptor modulation.